Sistema de Salut de Catalunya
Institut Català de la Salut
[Pronsati N] Colorado, USA. [Liu G] Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. [Bauer TM] Greco-Hainsworth Centers for Research/Tennessee Oncology, PLLC, Nashville, TN, USA. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Goto Y] Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan. [Green G] Stellarton, Nova Scotia, Canada
Vall d'Hebron Barcelona Hospital Campus
2025-10-03T07:57:53Z
2025-10-03T07:57:53Z
2025-08
Adverse event; Anaplastic lymphoma kinase; Non-small cell lung cancer
Esdeveniment advers; Cinasa del limfoma anaplàsic; Càncer de pulmó de cèl·lules no petites
Evento adverso; Cinasa del linfoma anaplásico; Cáncer de pulmón de células no pequeñas
Lorlatinib is an oral treatment for patients with advanced ALK-positive non-small cell lung cancer (NSCLC). Its efficacy was demonstrated in the CROWN clinical study, in which data from 5 years of follow-up demonstrated effective long-term disease control in patients with advanced ALK-positive NSCLC. While lorlatinib has a distinct side effect profile, its side effects are generally manageable. Managing side effects successfully is critical to preserving patient quality of life and promoting adherence to treatment—both of which are key to maximizing the long-term benefits of lorlatinib. The CROWN study showed that lorlatinib-associated side effects can be managed with dose adjustments, such as lowering the daily dose, without sacrificing treatment effectiveness. This guide, developed collaboratively by patients living with advanced ALK-positive NSCLC and healthcare professionals experienced with managing lorlatinib treatment, aims to help patients understand what to expect from treatment and how to take an informed, active role in their care.
Development of this report was funded by Pfizer.
Article
Versió publicada
Anglès
Pulmons - Càncer - Tractament; Posologia; Proteïnes quinases - Inhibidors - Ús terapèutic - Efectes secundaris; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors; Other subheadings::Other subheadings::/therapeutic use; DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung; Other subheadings::Other subheadings::Other subheadings::/adverse effects; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas; Otros calificadores::Otros calificadores::/uso terapéutico; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas; Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
Elsevier
Lung Cancer;206
https://doi.org/10.1016/j.lungcan.2025.108662
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3440]
